RETROSPECTIVE ANALYSIS OF RECURRENT HOSPITAL ADMISSIONS DUE TO GOUT AND THE ASSOCIATED COMORBIDITIES AT A TERTIARY CARE HOSPITAL by Niaz Hussain1* , Muhammad Iqbal 2 , Nasrullah Aamir3
IAJPS 2017, 4 (06), 1476-1480                       Niaz Hussain et al                        ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 1476 
 
       CODEN [USA]: IAJPBB                          ISSN: 2349-7750 
INDO AMERICAN JOURNAL OF              
PHARMACEUTICAL SCIENCES 
 
 
Available online at: http://www.iajps.com                                      Research Article 
 
RETROSPECTIVE ANALYSIS OF RECURRENT HOSPITAL 
ADMISSIONS DUE TO GOUT AND THE ASSOCIATED 
COMORBIDITIES AT A TERTIARY CARE HOSPITAL 
Niaz Hussain1*, Muhammad Iqbal 2, Nasrullah Aamir3 
1Niaz Hussain; MBBS, FCPS, Department of Orthopedics, Liaquat University of Medical and 
Health Sciences, Jamshoro, E-mail: niaz_h@hotmail.com 
2Muhammad Iqbal; MBBS, FCPS, Department of Medicine, Liaquat University of Medical and 
Health Sciences, Jamshoro, E-mail: muhammadiqbalshah22@gmail.com 
3Nasrullah Aamir; MBBS, FCPS,Department of Medicine, Peoples University of  Medical and 
Health Sciences, Nawabshah, E-mail: aamer.nasrullah@gmail.com 
                             
Abstract: 
Objective:To analyze recurrent hospital admissions to the hospital due to gout and associated comorbidities 
Methodology:The retrospective analysis is based upon the hospital records of 200 consecutive patients (non-probability-
consecutive sampling)  presenting again to the study setting (after prior admission and discharge) due to gout and its associated 
comorbidities from January 2016 to December 2016. The characteristics of all the patients and the recurrent admissions were 
analyzed as individual variables and analyzed using SPSS v. 19.0 and Microsoft Excel 2016.  
Results:A total of 200 admissions due of gout were aggravated by their respective comorbidities, meriting re-admission. The 
comorbidities meriting re-admission included hypertension (40%), renal anomalies (25%) and diabetes mellitus (30%). 5% of 
the re-admissions were due to gout alone, without any comorbidity.  
Conclusion:This study is the first of its kind, to analyze the re-admission of gout patients and the spectrum of comorbidities 
behind the re-admissions a tertiary care hospital in a major city of Hyderabad. The hospital plays host to a wide array of 
patients hailing from diverse sociodemographic backgrounds.  
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INTRODUCTION: 
Gout is a well-known and frequently occurring type 
of inflammatory arthritis brought about by the 
synthesis of uric acid crystals in the skeletal junctions 
of the body. Data from the western world (United 
States, United Kingdom, New Zealand and Australia) 
shows that gout prevalence is on the rise [1, 2]. 
In addition to being a significant burden on the 
healthcare system, gout exhibits hazardous effects on 
individuals and the society at large. It reduces ones 
health related quality of life, weakens one’s ability to 
function as a healthy and effective unit of the society 
thus costing the individual and the society on 
multiple levels. [3, 4] Furthermore, the reduced 
ability of a person to serve as an effective and 
productive unit of society stems from impairment, 
debility and disability and leads to impaired work 
productivity [5, 6].  
All members of the society suffer from the stated ill-
effects of the disease but the age group that proves 
the most costly in-terms of damage to the society 
heightening of hospital burden are is the working 
adults (25-64 years) [7]. What is worse that fresh 
evidence suggest gout to be a poorly treated ailment 
is undertreated, and even when it is treated, the non-
adherence exhibited by the patients paints a grim 
picture. [8, 9] 
Gout, apart from being troublesome on its own, 
serves as an independant contributory factor towards 
diseases of cardiovascular origin. It is responsible for 
hike in the all cause-mortality rates of the society and 
also contributes to the greater prevalence of medical 
comorbidities in the society [4, 10]. The fact that 
diseases of cardiovascular origin (including 
hypertension), endocrine disorders (especially 
diabetes mellitus) and renal anomalies are all 
common in patients suffering from gout patients 
supports this claim [11–14].  
Thus research also reiterates the claim that the 
severity of gout is heightened with the increasing 
number of comorbidities and ads to the hospital 
burden by increasing the likelihood of re-admission 
to the hospitals [12].As stated above, this research 
has numerous novel aspects imbedded. Not only does 
this research take tap into the untouched hospital re-
admission data that provides useful insight into the 
true hospital burden, it also analyzed separately the 
readmissions brought about not only by gout alone 
but the spectrum of comorbidities as well. [12, 13] 
We hope that our research will provide the much 
needed observational data that shall serve as the basis 
for further research to devise interventions aimed at 
reducing the number of hospital re-admissions and 
thus the burden on the resources of health sector. 
METHODOLOGY: 
The retrospective analysis is based upon the hospital 
records of 200 consecutive patients (non-probability-
consecutive sampling)  presenting again to the study 
setting (after prior admission and discharge) due to 
gout and its associated comorbidities from January 
2016 to December 2016. The characteristics of all the 
patients and the recurrent admissions were analyzed 
as individual variables and analyzed using SPSS v. 
19.0 and Microsoft Excel 2016.  
RESULTS: 
A total of 800 gout patients presented at the study 
setting, out of which 200 presented back to the 
hospital at least one more time after initial discharge 
from the hospital. 
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The re-admissions were often due to a variety of comorbidities aggravating the primary disease i.e. gout. 5% of the 
re-admissions were due to gout alone, without any comorbidity, while 95% of the times, the re-admission were 
merited aggravated health condition due to comorbidities. 
 
 
 
The comorbidities meriting re-admission included hypertension (40%), renal anomalies (25%) and diabetes mellitus 
(30%). 
 
 
DISCUSSION: 
Our research is one of a kind in the developing world 
and entirely novel in Pakistan. The need to carry out 
a research is justified from the fact that the incidence 
of prevalence of gout is on a rise un-paralleled in 
history [1, 2]. The need for our research is further 
proved by numerous research studies that suggest that 
comorbidities are common in gout and add to the 
overall health burden due to the disease. Literature 
also explicitly states that the incidence of hospital 
admission is increased with the increasing number of 
comorbidities. [11–16]. 
A considerable number of patients presented to the 
hospital again seeking re-admission after initial 
discharge from the hospital. It can be safely assumed 
that those presenting again were either victim to 
treatment resistant gout, or they suffered from the 
basic flaws e.g. inadequate/unsuitable treatment, 
poor-treatment adherence or both. These factors have 
been found extensively in literature, especially 
treatment non-adherence [8]. Exploring further the 
phenomenon of non-adherence to treatment among 
people of gout, an extensive review of literature 
reveals that skipping allopurinol dosing often is to 
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blame for deteriorating the condition to an extent that 
re-admission becomes necessary [17, 18]. 
The results yielded by our retrospective analysis 
compare and contrast, on different levels, to the 
results of international cohorts of great repute [11–
14]. Our results show that the rates of one of the most 
common comorbidity, diabetes mellitus were high i.e. 
30%, when compared to those shown in the cohorts 
of Annemans (8.3%) and Wu (18.4% and 18.5%) 
[11, 12]. On the contrary, the hypertension rate 
yielded in our result i.e. 40% was lesser when 
compared to other cohorts, such as Phipps-Green 
(52–66%) and Riedel (58%) [19, 20].  
Reviewing literature at length and drawing further 
comparisons, it was revealed that the rates of renal 
disease in cohorts such as Annemans primary care 
cohort (5–10%) were lower when compared to our 
rate of 25%. However other cohorts such as Phipps-
Green (30–35%) and Wu (29–30%) yielded rates 
higher than our study [12, 14].  
Overall we encountered 800 patients presenting with 
gout during the study duration and judging by this 
high turnout, it is safe to assume that the incidence 
and prevalence in our study setting has rates to be 
adversely reckoned. It leads ahead and the rates of 
incidence and prevalence in reputed published 
cohorts [11, 12, 14, 19 & 20].  
The current condition is worrisome on multiple 
levels. Firstly, the incidence and prevalence of the 
disease is on the rise and consequently the rates of 
primary admission are increasing and thus adding to 
the already high healthcare burden. Secondly, owing 
to factors such as inadequate treatment, treatment 
non-adherence the re-admission rates are climbing. 
The re-admission rates are further increased due the 
heightened number of comorbidities making the 
health related quality of life. [21] 
So what do we owe this rise? Evidence exists, linking 
the disease under discussion (I.e. gout) to 
comorbidities such as diabetes mellitus, renal 
anomalies and hypertension but the extent remains 
debatable [22–24]. Further research needs to be 
conducted to ascertain the debatable aspects. 
CONCLUSION: 
This study is the first of its kind, to analyze the re-
admission of gout patients and the spectrum of 
comorbidities behind the re-admissions a tertiary care 
hospital in a major city of Hyderabad. The hospital 
plays host to a wide array of patients hailing from 
diverse sociodemographic backgrounds.  
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